This is where we share the valuable insights we've learned from our years of experience in decentralized clinical trials. Scroll down to see our latest content.
Many clinical trial sponsors don’t understand how decentralized clinical trials (DCTs) fit within today’s regulatory landscape. This lack of familiarity with decentralized research and regulatory approaches has created DCT hesitancy among sponsors.
Patient engagement in clinical trials can make or break a study. Engaged patients are more likely to participate and complete studies, which can strengthen data collection and, ultimately, provide more robust therapeutic evidence of safety and efficacy.
Clinical trials lay the foundation for breakthrough drugs, digital therapeutics, and medical devices—and, at the center of these studies are the patients.
In three short years, decentralized clinical trials (DCTs) have turned skeptics into believers. Trial sponsors who were once hesitant are now embracing the DCT model—and for good reason. Today’s DCTs are addressing longstanding industry challenges, expanding access to patients and clinicians, increasing diversity, accelerating cohort recruitment, and improving retention.